Alumis Inc. - חוב לטווח קצר של החברה ALMS

Alumis Inc. (ALMS) specializes in developing cutting-edge medications for the treatment of nervous system disorders and immune malfunctions. The price action history below illustrates market expectations, while the specific short-term debt metric stands at 0.00. The business relies on the high scalability of its developments, enabling the rapid expansion of unique formulas into the global market with low per-unit production costs.

Short-term debt records the total obligations of Alumis Inc. with a maturity of up to one year. This metric measures liquidity and default risk, accounting for volatility between quarterly reports. Current financial debt at 0.00 allows for the precise rebalancing of asset weights. Low values confirm the absence of capital expenditures on plants. Outsourcing production and testing minimizes the debt load of Alumis Inc.